Animal StudyPubMed ID: 37148932·2023

MOTS-c reverses high-fat diet-induced insulin resistance through AMPK activation

Kim SJ, Xiao T, Wang K, et al.

Diabetes, 2023

Key finding

MOTS-c treatment improved insulin tolerance (HOMA-IR: 4.2 to 1.9) and increased AMPK-phosphorylated/total AMPK ratio from 0.18 to 0.71 in muscle.

Summary

MOTS-c administration in high-fat diet-fed mice restores insulin sensitivity through phosphorylation of AMPK and downstream PGC-1α signaling.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

MOTS-cL2

A mitochondria-derived peptide that targets the AMPK pathway, studied for metabolic regulation and exercise mimicry.

More research on MOTS-c

Human pilot study: MOTS-c supplementation improves insulin sensitivity

Journal of Clinical Endocrinology & Metabolism · 2025 · Human Pilot

Mitochondrial-derived peptide MOTS-c mediates beneficial metabolic effects of exercise

Cell Reports · 2024 · Animal Study

MOTS-c analog development and pharmacokinetics: oral bioavailability enhancement

Biochemical Pharmacology · 2024 · Animal Study

MOTS-c enhances glucose uptake through AMPK-independent mechanisms in muscle

Metabolism: Clinical & Experimental · 2024 · Animal Study

MOTS-c and liver metabolism: effects on hepatic glucose production and lipid metabolism

Journal of Hepatology · 2024 · Animal Study